What is HC Wainwright’s Estimate for JSPR FY2030 Earnings?

Jasper Therapeutics, Inc. (NASDAQ:JSPR) – Stock analysts at HC Wainwright issued their FY2030 earnings estimates for Jasper Therapeutics in a research note issued to investors on Tuesday, March 31st. HC Wainwright analyst E. Bodnar anticipates that the company will post earnings of ($0.75) per share for the year. The consensus estimate for Jasper Therapeutics’ current full-year earnings is ($4.47) per share.

Several other equities analysts also recently weighed in on the company. UBS Group assumed coverage on Jasper Therapeutics in a research note on Monday, March 23rd. They issued a “neutral” rating for the company. Rodman & Renshaw started coverage on Jasper Therapeutics in a research report on Tuesday, January 13th. They set a “buy” rating and a $17.00 target price on the stock. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Jasper Therapeutics in a report on Thursday, January 22nd. Six research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $19.88.

Jasper Therapeutics Trading Down 14.0%

JSPR stock opened at $0.69 on Wednesday. The firm has a 50 day moving average of $1.28 and a 200-day moving average of $1.75. The company has a market cap of $19.25 million, a price-to-earnings ratio of -0.15 and a beta of 3.20. Jasper Therapeutics has a 12-month low of $0.69 and a 12-month high of $7.19.

Jasper Therapeutics (NASDAQ:JSPR) last issued its earnings results on Monday, March 30th. The company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.79) by $0.47.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of JSPR. Quadrature Capital Ltd purchased a new stake in Jasper Therapeutics in the 4th quarter valued at approximately $123,000. Millennium Management LLC increased its position in Jasper Therapeutics by 194.2% during the fourth quarter. Millennium Management LLC now owns 1,073,783 shares of the company’s stock worth $1,965,000 after buying an additional 708,844 shares in the last quarter. Engineers Gate Manager LP acquired a new position in shares of Jasper Therapeutics in the fourth quarter worth $26,000. Boothbay Fund Management LLC lifted its position in shares of Jasper Therapeutics by 79.4% in the fourth quarter. Boothbay Fund Management LLC now owns 793,954 shares of the company’s stock valued at $1,453,000 after acquiring an additional 351,312 shares in the last quarter. Finally, ADAR1 Capital Management LLC purchased a new stake in shares of Jasper Therapeutics in the fourth quarter valued at $256,000. 79.85% of the stock is currently owned by institutional investors and hedge funds.

About Jasper Therapeutics

Jasper Therapeutics, Inc (NASDAQ: JSPR) is a clinical-stage biopharmaceutical company focused on translating advances in immunobiology into therapies for serious and rare diseases with unmet medical needs. The company’s research and development efforts center on engineered biologics and cell-based approaches designed to address complications in hematologic conditions and improve outcomes in transplant medicine.

Central to Jasper’s pipeline is JSP191, a monoclonal antibody targeting the CD117 receptor, which is being evaluated to enhance donor hematopoietic stem cell engraftment in patients undergoing stem cell transplantation.